Lowenstein represented First Wave BioPharma, Inc. in the transaction. First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic...
This content is for Standard 1 Year members only. LoginJoin Now